treatment for advanced prostatic cancer / cell culture media / Cancer Treat / treatment of castration-resistant prostate cancer / Treatment of androgen-independent prostate cancer / prostate cancer treatment / treatment of advanced prostate cancer / pharmaceuticals / prostate cancer therapy / in vivo model systems / /
MedicalCondition
androgen-independent prostate cancer / primary / solid organ metastasis / advanced prostatic carcinoma / recurrent prostate cancer / metastatic prostate cancer / Male pseudohermaphroditism / castration-resistant prostate cancer / disseminated prostatic cancer / post-orchiectomy prostatic cancer / bone marrow metastasis / D prostate cancer / CWR22 tumor / castration-resistant metastatic prostate cancer / Prostatic Hypertrophy / J Cancer / metastatic castration-resistant prostate cancer / prostatic cancer / advanced hormone-refractory prostate cancer / independent prostate cancer / reactivated carcinoma / castration-resistant tumor / hypersensitivity / Prostate cancer / resistant prostate cancer / MS / previously untreated prostatic cancer / adrenal insufficiency / tumor / advanced prostate cancer / Cancer / tumors / disease / prostatic carcinoma / advanced prostatic cancer / castration-recurrent prostate cancer / metastatic carcinoma / tumor cell / After CWR22 tumor / CWR22 human prostate cancer / human prostate cancer / hormone-independent prostate cancer / multitarget prostate cancer / primary human prostatic carcinoma / CWR22 prostate cancer / Potent anti-prostate cancer / androgen-dependent human prostate cancer / /
MedicalTreatment
chemotherapy / hormone therapy / Surgery / cancer therapy / hormonal therapy / /
Organization
Med Assoc / Department of Urology / FDA / Roswell Park Cancer Institute / /
Person
Clin Endocrinol / Titus M. Tissue / Elm Streets / Ann Surg / Griffiths K. Steroids / Arch Intern / James L. Mohler / Carlton Streets / / /
Int. J. Biol. Sci. 2014, Vol. 10 Ivyspring International Publisher 596